Lynn Seely
Directeur Général chez LYELL IMMUNOPHARMA, INC.
Fortune : 763 221 $ au 30/04/2024
Profil
Lynn Seely is currently the President, Chief Executive Officer & Director at Lyell Immunopharma, Inc. since 2022.
She is also an Independent Director at Blueprint Medicines Corp.
since 2016.
Previously, she served as the Chief Executive Officer of Myovant Sciences, Inc. from 2019 to 2020 and as the President, Chief Executive Officer & Director of Myovant Sciences Ltd.
from 2016 to 2021.
Dr. Seely also held positions at Chiron Corp.
as an Associate Director-Clinical Development from 1996 to 2000, at Orion Acquisition Corp.
II as the Chief Medical Officer in 2005, at Anesiva, Inc. as the Vice President-Clinical Development from 2002 to 2005, at Pro-Duct Health, Inc. as the Vice President-Clinical Development from 2000 to 2001, and at the University of California San Diego as a Faculty Member from 1992 to 1996.
She was also the Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015, the Vice President-Clinical Development at Cytyc Health Corp.
from 2001 to 2002, and the Vice President-Clinical Development at Corgentech, Inc. in 2005.
Dr. Seely's education includes an undergraduate degree from the University of Oklahoma in 1981 and a doctorate degree from the University of Oklahoma College of Medicine in 1985.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 8 412 ( 0,01% ) | 763 221 $ | 30/04/2024 |
Postes actifs de Lynn Seely
| Sociétés | Poste | Début |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Directeur/Membre du Conseil | 14/04/2016 |
| LYELL IMMUNOPHARMA, INC. | Directeur Général | 15/12/2022 |
Anciens postes connus de Lynn Seely
| Sociétés | Poste | Fin |
|---|---|---|
| MYOVANT SCIENCES LTD. | Directeur Général | 01/01/2021 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Directeur Général | 04/01/2020 |
| MEDIVATION INC | Directeur Technique/Scientifique/R&D | 15/10/2015 |
| Orion Acquisition Corp. II | Directeur Technique/Scientifique/R&D | 29/06/2005 |
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/03/2005 |
Formation de Lynn Seely
| University of Oklahoma | Undergraduate Degree |
| University of Oklahoma College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
| Orion Acquisition Corp. II | Finance |
Anesiva, Inc.
Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | Health Technology |
Pro-Duct Health, Inc.
 Pro-Duct Health, Inc. Medical SpecialtiesHealth Technology Pro·Duct Health manufactures the devices used in ductal lavage. The company is dedicated to eradicating breast cancer by enabling the earliest possible detection of breast pre-cancer and cancer | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
| Cytyc Health Corp. | |
| Corgentech, Inc. | Health Technology |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
